Literature DB >> 20118950

Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate.

Gideon Sartorius1, Carolyn Fennell, Sasa Spasevska, Leo Turner, Ann J Conway, David J Handelsman.   

Abstract

Pain following depot intramuscular (IM) injection of oil vehicle-based drugs has been little studied. This study aimed to determine prospectively the prevalence, determinants, severity and functional consequences of pain during the week after IM injection of 1 000 mg testosterone undecanoate (TU) in a 4-mL castor oil vehicle. Androgen-deficient men receiving regular T replacement therapy at an academic andrology clinic were recruited to report pain scores using a coloured visual linear analogue scale at seven times over the first day and daily for a week after a deep IM gluteal injection. The time course and covariables influencing pain scores were analysed by mixed model analysis of variance (ANOVA). Following 168 injections in 125 men, pain was reported by 80% of men, peaking immediately after injection, reaching only moderate severity, lasting 1-2 days and returning to baseline by day 4. The pain required little analgesic use and produced minimal interference in daily activities. The time course of pain scores was reproducible in the 43 men who underwent two consecutive injections. Pain was more severe in men who had an earlier painful injection, but less severe in older and more obese men. There were negligible differences in post-injection pain experience between experienced nurses administering injections. Deep IM gluteal injection of depot TU in 4-mL castor oil is well tolerated and post-injection pain is influenced by earlier painful injection experience, as well as age and obesity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118950      PMCID: PMC3739103          DOI: 10.1038/aja.2010.1

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  44 in total

1.  Long-acting steroids in reproduction.

Authors:  K JUNKMANN
Journal:  Recent Prog Horm Res       Date:  1957

2.  Simulation of cancer by oil granulomas of therapeutic origin.

Authors:  W S SYMMERS
Journal:  Br Med J       Date:  1955-12-24

Review 3.  Preventing sciatic nerve injury from intramuscular injections: literature review.

Authors:  Sandra P Small
Journal:  J Adv Nurs       Date:  2004-08       Impact factor: 3.187

4.  Complications at site of injection of depot neuroleptics.

Authors:  J Hay
Journal:  BMJ       Date:  1995-08-12

5.  Intramuscular injection of drugs.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

6.  Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men.

Authors:  M Cristina Meriggiola; S Cerpolini; W J Bremner; M T Mbizvo; K M Vogelsong; G Martorana; G Pelusi
Journal:  Hum Reprod       Date:  2006-05-26       Impact factor: 6.918

7.  Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume.

Authors:  C F Minto; C Howe; S Wishart; A J Conway; D J Handelsman
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

8.  Pain sensitivity and obesity.

Authors:  M J McKendall; R J Haier
Journal:  Psychiatry Res       Date:  1983-02       Impact factor: 3.222

9.  A comparative study of serum creatine phosphokinase (CPK) activity in rabbits, pigs and humans after intramuscular injection of local damaging drugs.

Authors:  E Steiness; F Rasmussen; O Svendsen; P Nielsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-05

10.  Pain sensitivity in obesity.

Authors:  B Zahorska-Markiewicz; P Zych; C Kucio
Journal:  Acta Physiol Pol       Date:  1988 May-Jun
View more
  8 in total

1.  Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model.

Authors:  Vincent H Tam; Daniel N Cohen; Kimberly R Ledesma; Bobby Guillory; Katrina Chan; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review.

Authors:  Jarren A Adam; Alexander W Pastuszak; Michael B Christensen; Rachel Spencer; Ashlynn Sandberg; James M Hotaling; Larry I Lipshultz
Journal:  Int J Impot Res       Date:  2022-05-24       Impact factor: 2.896

3.  Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option.

Authors:  Maria Gabriela Figueiredo; Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2022-02-17       Impact factor: 5.958

4.  Novel double-layer Silastic testicular prosthesis with controlled release of testosterone in vitro, and its effects on castrated rats.

Authors:  Hui-Xing Chen; Shi Yang; Ye Ning; Hai-Hao Shao; Meng Ma; Ru-Hui Tian; Yu-Fei Liu; Wei-Qiang Gao; Zheng Li; Wei-Liang Xia
Journal:  Asian J Androl       Date:  2017 Jul-Aug       Impact factor: 3.285

5.  Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.

Authors:  Leo Turner; Lam P Ly; Reena Desai; Gurmeet K S Singh; Timothy D Handelsman; Sasha Savkovic; Carolyn Fennell; Veena Jayadev; Ann Conway; David J Handelsman
Journal:  J Endocr Soc       Date:  2019-06-28

6.  Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study.

Authors:  Jed Kaminetsky; Jonathan S Jaffe; Ronald S Swerdloff
Journal:  Sex Med       Date:  2015-09-17       Impact factor: 2.491

7.  Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis.

Authors:  Alexander W Pastuszak; Yiqun Hu; Jeffrey D Freid
Journal:  Sex Med       Date:  2020-03-14       Impact factor: 2.491

8.  Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men.

Authors:  Nandini Shankara Narayana; Lam P Ly; Veena Jayadev; Carolyn Fennell; Sasha Savkovic; Ann J Conway; David J Handelsman
Journal:  Endocr Connect       Date:  2021-07-14       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.